More…
Home » More...
Metformin Against Cancer?
Friday, September 3rd, 2010
It’s always good to hear about an older compound that may be doing good things that we didn’t realize. The current example is metformin, the diabetes drug known to many by its brand name Glucophage, but a generic compound for some years now.
Posted in: Clinical Trials | 0 Comments »
Read the full story
Posters and Pickiness
Thursday, September 2nd, 2010
Blogging time is short today, since I’m on a deadline to produce a couple of posters for presentation.
Posted in: Clinical Trials | 0 Comments »
Read the full story
How Long Would It Take – If Everything Worked?
Wednesday, September 1st, 2010
Over at BoingBoing, they’re investigating the question: “How long would your PhD have taken if everything worked the first time ?” I have to admit, it took me a few minutes to adjust my head to that idea, since God knows, nothing in my PhD ever looked like working the first time. And it’s a hard one to answer, because I had to do some backtracking, as so often happens in total synthesis
Posted in: Clinical Trials | 0 Comments »
Read the full story
Scientia Est Experentia
Wednesday, September 1st, 2010
Chad Orzel has a post up on the two halves of physics, and about how people tend to forget one of them: the experimentalists. I think he’s right, and the problem is the glamorous coating that began to stick to theoretical physics in the early 20th century (and has never completely flaked away)
Posted in: Clinical Trials | 0 Comments »
Read the full story
Scientia Est Experientia
Wednesday, September 1st, 2010
Chad Orzel has a post up on the two halves of physics, and about how people tend to forget one of them: the experimentalists. I think he’s right, and the problem is the glamorous coating that began to stick to theoretical physics in the early 20th century (and has never completely flaked away)
Posted in: Clinical Trials | 0 Comments »
Read the full story
BioMarin Pipeline Update
Wednesday, September 1st, 2010
Zacks.com submits: Recently, BioMarin Pharmaceutical Inc.’s ( BMRN ) pipeline received a boost with the US Food and Drug Administration (FDA) granting orphan drug status to its candidate BMN-701, which is being developed to combat Pompe disease. The investigational new drug (IND) application for the candidate, which has been effective in pre-clinical studies, was accepted by the FDA with clinical trials expected to commence in the first quarter of 2011
Read the full story
Nanopowders?
Tuesday, August 31st, 2010
Here’s a lab question for everyone. I have a bottle of Aldrich copper oxide nanopowder on my lab bench; I’ve been meaning to try it out for some Ullmann reactions.
Posted in: Clinical Trials | 0 Comments »
Read the full story
Avastin For Metastatic Breast Cancer: The Whole Story
Monday, August 30th, 2010
Here’s an excellent roundup of the Avastin story, referenced in an earlier post here . I have to say, I’ve been disappointed in some of the commentary on this issue (which that article goes into as well). Too many people have jumped right to the conclusion that yep, here’s what the new health care plan is going to do to us, yank life-saving medicines out of our hands because they cost too much
Posted in: Clinical Trials | 0 Comments »
Read the full story
Roche: Layoffs, or Rumors?
Monday, August 30th, 2010
A Swiss newspaper reported over the weekend that Roche is planning large cuts, across much of their multinational organization. Here’s the original article , for those of you who read German. Looking it over, it seems to depend on the word of one Roche insider – or, more accurately, someone the newspaper describes as having the “best contacts” there
Posted in: Clinical Trials | 0 Comments »
Read the full story
How About The Same Price You Turned Down Before? Hmm?
Monday, August 30th, 2010
Well, so much for my fantasy of Sanofi-Aventis walking away from their attempt to buy Genzyme. They went public yesterday with a $69/share offer – even lower than most people were thinking – and just a little while ago, Genzyme publicly turned them down . What’s more, this is apparently the same price at which Genzyme (privately) balked earlier in the summer
Posted in: Clinical Trials | 0 Comments »
Read the full story
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice